Published in Cell on January 14, 2005
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol (2008) 4.81
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Targeting the ubiquitin system in cancer therapy. Nature (2009) 3.27
A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev (2006) 2.41
Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol (2006) 2.21
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer (2005) 1.64
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration. EMBO J (2006) 1.54
Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci U S A (2009) 1.50
Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev (2005) 1.42
Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A (2007) 1.41
p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC. Mol Cell Biol (2007) 1.37
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol (2010) 1.33
Mutant p53 mediates survival of breast cancer cells. Br J Cancer (2009) 1.33
Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol (2008) 1.32
miRNA response to DNA damage. Trends Biochem Sci (2011) 1.32
Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest (2007) 1.30
BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol (2007) 1.29
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene (2008) 1.26
Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A (2008) 1.18
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer (2011) 1.15
A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J (2007) 1.10
Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One (2009) 1.08
HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer (2009) 1.08
miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res (2011) 1.03
p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab (2005) 1.01
Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal (2007) 0.99
Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res (2006) 0.97
HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging (Albany NY) (2011) 0.97
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther (2008) 0.96
Human Delta1-pyrroline-5-carboxylate synthase: function and regulation. Amino Acids (2008) 0.96
Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun (2013) 0.95
NGF-mediated transcriptional targets of p53 in PC12 neuronal differentiation. BMC Genomics (2007) 0.93
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics (2008) 0.92
Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system. RNA (2006) 0.91
Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J Biol Chem (2011) 0.90
Functional genomics and SNP analysis of human genes encoding proline metabolic enzymes. Amino Acids (2008) 0.90
Combined effects of genetic variants of the PTEN, AKT1, MDM2 and p53 genes on the risk of nasopharyngeal carcinoma. PLoS One (2014) 0.88
NEK9-dependent proliferation of cancer cells lacking functional p53. Sci Rep (2014) 0.87
ARF-BP1 as a potential therapeutic target. Br J Cancer (2006) 0.86
Transcriptional Regulation of the p53 Tumor Suppressor Gene in S-Phase of the Cell-Cycle and the Cellular Response to DNA Damage. Biochem Res Int (2012) 0.86
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res (2011) 0.86
APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proc Natl Acad Sci U S A (2013) 0.86
Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. PLoS One (2013) 0.84
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res (2011) 0.83
Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS One (2010) 0.83
A p53-dependent promoter associated with polymorphic tandem repeats controls the expression of a viral transcript encoding clustered microRNAs. RNA (2010) 0.82
Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget (2016) 0.80
Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics. PLoS One (2012) 0.80
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. Br J Cancer (2007) 0.80
MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget (2015) 0.80
Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem (2007) 0.80
Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage. Mol Cell Biol (2015) 0.79
Mutant p53 protein expression and antioxidant status deficiency in breast cancer. EXCLI J (2014) 0.79
Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol (2009) 0.78
dNTP Supply Gene Expression Patterns after P53 Loss. Cancers (Basel) (2012) 0.78
Translational Control Protein 80 Stimulates IRES-Mediated Translation of p53 mRNA in Response to DNA Damage. Biomed Res Int (2015) 0.78
Structural Basis of Targeting the Exportin CRM1 in Cancer. Cells (2015) 0.77
Selective killing of Smad4-negative tumor cells via a designed repressor strategy. Mol Pharmacol (2008) 0.75
Cell cycle specific distribution of killin: evidence for negative regulation of both DNA and RNA synthesis. Cell Cycle (2015) 0.75
Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget (2016) 0.75
Supercritical-Carbon Dioxide Fluid Extract from Chrysanthemum indicum Enhances Anti-Tumor Effect and Reduces Toxicity of Bleomycin in Tumor-Bearing Mice. Int J Mol Sci (2017) 0.75
MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway. Cell Death Differ (2017) 0.75
p53 in the game of transposons. Bioessays (2016) 0.75
Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosourea-induced thymic lymphoma in C57BL/6 mice. Oncol Lett (2017) 0.75
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
Regulation of p53 activity through lysine methylation. Nature (2004) 5.78
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A (2010) 4.18
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell (2007) 3.56
Transcriptional regulation by p53. Cold Spring Harb Perspect Biol (2010) 3.16
TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell (2009) 3.15
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J (2006) 2.21
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07
p53 linear diffusion along DNA requires its C terminus. Mol Cell (2004) 2.03
Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell (2009) 2.00
The Chk2 protein kinase. DNA Repair (Amst) (2004) 1.85
Unleashing the power of p53: lessons from mice and men. Genes Dev (2006) 1.76
APC/C(Cdc20) targets E2F1 for degradation in prometaphase. Cell Cycle (2010) 1.62
Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell (2002) 1.57
Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry. Genes Dev (2013) 1.57
p53-Dependent induction of PVT1 and miR-1204. J Biol Chem (2011) 1.56
DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol (2005) 1.56
Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle (2009) 1.55
Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med (2011) 1.52
Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol (2002) 1.43
A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev (2009) 1.42
A role for caspase 2 and PIDD in the process of p53-mediated apoptosis. Proc Natl Acad Sci U S A (2008) 1.40
Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol Cell (2003) 1.39
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol (2011) 1.39
p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol (2003) 1.36
The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol (2010) 1.35
p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res (2003) 1.35
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene (2002) 1.35
Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci U S A (2012) 1.30
Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem (2003) 1.29
Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J Biol Chem (2006) 1.28
Mutational analysis of the p53 core domain L1 loop. J Biol Chem (2006) 1.25
p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation. J Cell Sci (2008) 1.24
Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One (2013) 1.22
p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. Mol Cell Biol (2006) 1.20
The S phase checkpoint: when the crowd meets at the fork. Semin Cell Dev Biol (2005) 1.20
MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A (2013) 1.19
Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell (2012) 1.19
p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc Natl Acad Sci U S A (2011) 1.10
Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle (2008) 1.09
Mutant p53 gain of function: the NF-Y connection. Cancer Cell (2006) 1.08
Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem (2003) 1.05
P53 and aging: A fresh look at an old paradigm. Aging (Albany NY) (2010) 1.05
p53 in the cytoplasm: a question of overkill? Cell (2004) 1.05
Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J Biol Chem (2002) 1.04
Inhibition of TFII-I-dependent cell cycle regulation by p53. Mol Cell Biol (2005) 1.00
DECOD: fast and accurate discriminative DNA motif finding. Bioinformatics (2011) 0.98
p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res (2006) 0.98
p53 and Metabolism: The GAMT Connection. Mol Cell (2009) 0.98
Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress response. J Biol Chem (2009) 0.97
Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem (2003) 0.96
p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. J Cell Sci (2008) 0.95
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov (2011) 0.94
Deconstruction of p53 functions and regulation. Oncogene (2002) 0.94
Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation. Mol Cell Biol (2009) 0.90
MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol Cell Biol (2012) 0.89
UV-triggered p21 degradation facilitates damaged-DNA replication and preserves genomic stability. Nucleic Acids Res (2013) 0.88
Noncoding RNAs: the missing "linc" in p53-mediated repression. Cell (2010) 0.88
Mdm2 and MdmX as Regulators of Gene Expression. Genes Cancer (2012) 0.87
Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. J Biol Chem (2007) 0.87
p53 leans on its siblings. Cancer Cell (2002) 0.85
The linchpin? Pin1 meets p73. Cancer Cell (2004) 0.81
Replication of damaged DNA in vitro is blocked by p53. Nucleic Acids Res (2003) 0.80
Ribosomal protein L37 and the p53 network. Cell Cycle (2010) 0.80
Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. Cell Cycle (2009) 0.79
Lysine-independent turnover of cyclin G1 can be stabilized by B'alpha subunits of protein phosphatase 2A. Mol Cell Biol (2008) 0.79
Dissimilar DNA binding by p53 in normal and tumor-derived cells. Cell Cycle (2011) 0.78
Deconstructing nucleotide binding activity of the Mdm2 RING domain. Nucleic Acids Res (2010) 0.78
Mutant p53 succumbs to starvation. Cell Cycle (2013) 0.77
The p53-HAT connection: PCAF rules? Cell Cycle (2012) 0.75
Anything but simple: a phosphorylation-driven toggle within Brd4 triggers gene-specific transcriptional activation. Mol Cell (2013) 0.75